Retrospective comparison of ChatGPT-4 treatment recommendations with real-world physician management in newly diagnosed hypertension: a single-centre study

• by Kadri Murat Gürses, Hüseyin Tezcan, Abdullah Tunçez, Yasin Özen, Muhammed Ulvi Yalçın

• May 12, 2026

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

• by Kathryn Wighton

• May 21, 2026

• 2 min

FDA Approves Baxdrostat for Resistant Hypertension

Phase 3 findings support the oral therapy in adults with persistent blood pressure elevation despite multidrug treatment.

• by Kathryn Wighton

• May 18, 2026

• 2 min

Abnormal active myocardial relaxation by dipyridamole stress test in suspected early-stage heart failure with preserved ejection fraction: a retrospective exploratory analysis

• by Gabriella Locorotondo, Monica Filice, Francesca Augusta Gabrielli, Giacomo Moretti, Laura Manfredonia, Antonella Lombardo, Gaetano Antonio Lanza, Leonarda Galiuto

• May 28, 2026